Last updated on December 2018

Phase 3 Study of BGB-A317 Versus Sorafenib in Patients With Unresectable HCC


Brief description of study

This is a Phase 3, randomized, open-label, multicenter, global study designed to compare the efficacy and safety of BGB-A317 versus sorafenib as a first-line systemic treatment in patients with unresectable hepatocellular carcinoma. This study also includes a substudy investigating the safety, tolerability, PK, and preliminary efficacy in HCC in Japanese patients. In Japan, preliminary safety and tolerability will be evaluated (Safety Run-In Substudy) before Japanese patients are recruited in this Phase 3 study.

Clinical Study Identifier: NCT03412773

Contact Investigators or Research Sites near you

Start Over

Jeannie Hou, Senior Medical Director

Kyushu Medical Center
Fukuoka, Japan
2.09miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.